FFO
REGN icon

Fiduciary Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Fiduciary Family Office’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$798K Buy
1,280
+206
+19% +$140K 0.2% 86
2026
Q1 		$830K Buy
1,074
+94
+10% +$72K 0.24% 83
2025
Q4 		$756K Buy
980
+125
+15% +$84.9K 0.22% 81
2025
Q3 		$481K Buy
+855
New +$483K 0.14% 122

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Fiduciary Family Office's REGN Position: Q2 2026 in Review

Fiduciary Family Office increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, buying an estimated $140K and bringing the position to 1,280 shares worth $798K. The position accounts for 0.2% of the portfolio, ranked #86.

Fiduciary Family Office first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $830K in Q1 2026. 878 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Fiduciary Family Office held 1,280 shares of Regeneron Pharmaceuticals worth $798K as of Q2 2026.
  • Fiduciary Family Office bought 206 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $140K.
  • Regeneron Pharmaceuticals made up 0.2% of Fiduciary Family Office's portfolio in Q2 2026, its #86 holding.
  • Fiduciary Family Office first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Fiduciary Family Office's Regeneron Pharmaceuticals position peaked at $830K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fiduciary Family Office's 13F filing for Q2 2026, filed 5 Aug 2026.